FDA Approves gammaCore Sapphire: Non-Invasive Vagus Nerve Stimulation for Migraine Prevention
Device Overview
On October 14, the FDA cleared the gammaCore Sapphire—a handheld, non-invasive vagus nerve stimulator (nVNS)—for preventive treatment of episodic migraine in adults.
Mechanism of Action
The device delivers mild electrical stimulation through the skin to the cervical vagus nerve in the neck. Vagus nerve activation modulates pain pathways in the brainstem and cortex, reducing migraine frequency and severity.
Indications
Approved for adults (≥18 years) with episodic migraine (0–14 headache days/month). Not indicated for chronic migraine (≥15 headache days/month).
Usage Protocol
Hold device against the neck over the vagus nerve for 2 minutes per session (typically 2 stimulations per session). Up to 3 sessions daily as needed. Patients may feel a tingling sensation; intensity is adjustable.
Side Effects
Most common: application-site pain, discomfort, or redness. Less common: hoarseness, throat irritation, cough, nausea, dizziness. No serious adverse events reported in trials.
Clinical Efficacy
In pivotal trials, gammaCore Sapphire reduced monthly migraine days by ~50% and migraine severity by ~30% on average compared to baseline.
Cost and Access
Device cost: $1,995 (may be covered by some insurance plans). Available by prescription only. Discuss with your headache specialist or neurologist to determine suitability.
Migraine - Related Articles
- Migraine Vertigo: Causes, Symptoms & Relief Strategies
- Can Chiropractic Care Reduce Migraine Symptoms?
- Triptans: Understanding and Using Medications for Migraines & Cluster Headaches
- Can Dry Needling Help Treat or Prevent Migraine Headaches?
- Migraine Duration: What to Expect & When to Seek Help
- Understanding Migraine‑Related Eye Pain
- Vertigo Migraine: Symptoms, Causes & Treatment
